("PolyPid" or the "Company"), unveiled its long-acting GLP-1 receptor agonists (glucagon-like peptide-1 RA) delivery platform which aims to subcutaneously release GLP-1 RA for approximately 60 days, significantly longer than current weekly injection regimens
G30.9 Alzheimers disease, unspecified (used when monitoring memory-related drug therapy)
Participants who reported being somewhat likely (22%) or not likely (1%) to participate in other research interviews felt their interviews were too long/short (37%/4%) and/or would have preferred a different format (14% remote, 7% in-person and/or 4% written)
GLP-1 drugs help your body regulate levels of insulin (a hormone that lets your body use the food you eat for energy) and glucose
Regarding GLP-1 injections specifically, there is no known direct interaction with oral magnesium supplements
GLP-1 plays a key role in regulating blood sugar, appetite, and insulin secretion